Speeding up early drug discovery in antiviral research: A fragment-based in silico approach for the design of virtual anti-hepatitis C leads

ACS Combinatorial Science

Volumn 19, Issue 8, 2017, Pages 501-512

  Speck Planche, Alejandro ^a   Natalia Dias Soeiro Cordeiro, M ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

ADMET; Anti HCV activity; Contribution; Design; Fragments; Mtk QSBER; Quadratic indices; Screening

Indexed keywords

ANTIVIRUS AGENT; PROTEIN BINDING;

BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C; MULTIDRUG RESISTANCE; PROCEDURES; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTUM THEORY; THERMODYNAMICS;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, VIRAL; HEPACIVIRUS; HEPATITIS C; MODELS, BIOLOGICAL; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUANTUM THEORY; THERMODYNAMICS;

EID: 85028993709     PISSN: 21568952     EISSN: 21568944     Source Type: Journal    
DOI: 10.1021/acscombsci.7b00039     Document Type: Article

References (65)

1. Wree, A.; Broderick, L.; Canbay, A.; Hoffman, H. M.; Feldstein, A. E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 627−636.
2. Bernal, W.; Auzinger, G.; Dhawan, A.; Wendon, J. Acute liver failure. Lancet 2010, 376, 190−201.
3. Forner, A.; Llovet, J. M.; Bruix, J. Hepatocellular carcinoma. Lancet 2012, 379, 1245−1255.
4. Mohd Hanafiah, K.; Groeger, J.; Flaxman, A. D.; Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57, 1333−1342.
5. Mesalam, A. A.; Vercauteren, K.; Meuleman, P. Mouse systems to model hepatitis C virus treatment and associated resistance. Viruses 2016, 8, 176.
6. Negro, F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract. Res. Clin. Gastroenterol. 2010, 24, 183−192.
7. Paul, S. M.; Mytelka, D. S.; Dunwiddie, C. T.; Persinger, C. C.; Munos, B. H.; Lindborg, S. R.; Schacht, A. L. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discovery 2010, 9, 203−214.
8. Jahnke, W.; Erlanson, D. A. Fragment-Based Approaches in Drug Discovery; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2006.
9. Liao, C.; Sitzmann, M.; Pugliese, A.; Nicklaus, M. C. Software and resources for computational medicinal chemistry. Future Med. Chem. 2011, 3, 1057−1085.
10. Vrontaki, E.; Melagraki, G.; Mavromoustakos, T.; Afantitis, A. Searching for anthranilic acid-based thumb pocket 2 HCV NS5B polymerase inhibitors through a combination of molecular docking, 3D-QSAR and virtual screening. J. Enzyme Inhib. Med. Chem. 2016, 31, 38−52.
11. Yu, H.; Fang, Y.; Lu, X.; Liu, Y.; Zhang, H. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors. Chem. Biol. Drug Des. 2014, 83, 89−105.
12. Worachartcheewan, A.; Prachayasittikul, V.; Toropova, A. P.; Toropov, A. A.; Nantasenamat, C. Large-scale structure-activity relationship study of hepatitis C virus NS5B polymerase inhibition using SMILES-based descriptors. Mol. Diversity 2015, 19, 955−964.
13. Speck-Planche, A.; Dias Soeiro Cordeiro, M. N. Computer-aided drug design methodologies toward the design of anti-hepatitis C agents. Curr. Top. Med. Chem. 2012, 12, 802−813.
14. Therese, P. J.; Manvar, D.; Kondepudi, S.; Battu, M. B.; Sriram, D.; Basu, A.; Yogeeswari, P.; Kaushik-Basu, N. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model. 2014, 54, 539−552.
15. Wei, Y.; Li, J.; Qing, J.; Huang, M.; Wu, M.; Gao, F.; Li, D.; Hong, Z.; Kong, L.; Huang, W.; Lin, J. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking. PLoS One 2016, 11, e0148181.
16. Qureshi, A.; Kaur, G.; Kumar, M. AVCpred: an integrated web server for prediction and design of antiviral compounds. Chem. Biol. Drug Des. 2017, 89, 74−83.
17. Romero-Duran, F. J.; Alonso, N.; Yanez, M.; Caamano, O.; Garcia-Mera, X.; Gonzalez-Diaz, H. Brain-inspired cheminformatics of drug-target brain interactome, synthesis, and assay of TVP1022 derivatives. Neuropharmacology 2016, 103, 270−278.
18. Tenorio-Borroto, E.; Penuelas-Rivas, C. G.; Vasquez-Chagoyan, J. C.; Castanedo, N.; Prado-Prado, F. J.; Garcia-Mera, X.; Gonzalez-Diaz, H. Model for high-throughput screening of drug immunotoxicity - Study of the anti-microbial G1 over peritoneal macrophages using flow cytometry. Eur. J. Med. Chem. 2014, 72, 206−220.
19. Speck-Planche, A.; Kleandrova, V. V.; Ruso, J. M.; Dias Soeiro Cordeiro, M. N. First multitarget chemo-bioinformatic model to enable the discovery of antibacterial peptides against multiple Gram-positive pathogens. J. Chem. Inf. Model. 2016, 56, 588−598.
20. Speck-Planche, A.; Cordeiro, M. N. D. S. Enabling virtual screening of potent and safer antimicrobial agents against noma: mtk-QSBER model for simultaneous prediction of antibacterial activities and ADMET properties. Mini-Rev. Med. Chem. 2015, 15, 194−202.
21. Speck-Planche, A.; Cordeiro, M. N. D. S. Chemoinformatics for medicinal chemistry: in silico model to enable the discovery of potent and safer anti-cocci agents. Future Med. Chem. 2014, 6, 2013−2028.
22. Zhang, W.; Pei, J.; Lai, L. Computational Multitarget Drug Design. J. Chem. Inf. Model. 2017, 57, 403−412.
23. Hodos, R. A.; Kidd, B. A.; Shameer, K.; Readhead, B. P.; Dudley, J. T. In silico methods for drug repurposing and pharmacology. Wiley Interdiscip. Rev. Syst. Biol. Med. 2016, 8, 186−210.
24. Speck-Planche, A.; Cordeiro, M. N. D. S. Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery. Expert Opin. Drug Discovery 2015, 10, 245−256.
25. Herrera-Ibata, D. M.; Pazos, A.; Orbegozo-Medina, R. A.; Romero-Duran, F. J.; Gonzalez-Diaz, H. Mapping chemical structure-activity information of HAART-drug cocktails over complex networks of AIDS epidemiology and socioeconomic data of U.S. counties. BioSystems 2015, 132−133, 20−34.
26. Herrera-Ibata, D. M.; Pazos, A.; Orbegozo-Medina, R. A.; Gonzalez-Diaz, H. Mapping networks of anti-HIV drug cocktails vs. AIDS epidemiology in the US counties. Chemom. Intell. Lab. Syst. 2014, 138, 161−170.
27. Gonzalez-Diaz, H.; Herrera-Ibata, D. M.; Duardo-Sanchez, A.; Munteanu, C. R.; Orbegozo-Medina, R. A.; Pazos, A. ANN multiscale model of anti-HIV drugs activity vs AIDS prevalence in the US at county level based on information indices of molecular graphs and social networks. J. Chem. Inf. Model. 2014, 54, 744−755.
28. Kleandrova, V. V.; Speck Planche, A. Multitasking model for computer-aided design and virtual screening of compounds with high anti-HIV activity and desirable ADMET properties. In Multi-Scale Approaches in Drug Discovery: From Empirical Knowledge to In Silico Experiments and Back, 1st ed.; Speck-Planche, A., Ed. Elsevier: Oxford, UK, 2017; pp 55−81.
29. Speck-Planche, A.; Cordeiro, M. N. D. S. Simultaneous modeling of antimycobacterial activities and ADMET profiles: a chemoinformatic approach to medicinal chemistry. Curr. Top. Med. Chem. 2013, 13, 1656−1665.
30. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012, 40, D1100−1107.
31. Mok, N. Y.; Brenk, R. Mining the ChEMBL database: an efficient chemoinformatics workflow for assembling an ion channel-focused screening library. J. Chem. Inf. Model. 2011, 51, 2449−2454.
32. Warr, W. A. ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr. J. Comput.-Aided Mol. Des. 2009, 23, 195−198.
33. Tenorio-Borroto, E.; Garcia-Mera, X.; Penuelas-Rivas, C. G.; Vasquez-Chagoyan, J. C.; Prado-Prado, F. J.; Castanedo, N.; Gonzalez-Diaz, H. Entropy model for multiplex drug-target interaction endpoints of drug immunotoxicity. Curr. Top. Med. Chem. 2013, 13, 1636−1649.
34. ChemAxon Standardizer (Tool for Structure Canonicalization and Transformation), JChem., version 15.11.16.0; ChemAxon: Budapest, Hungary, 1998−2016.
35. Valdes-Martini, J. R.; García-Jacas, C. R.; Marrero-Ponce, Y.; Silveira Vaz ‘d Almeida, Y.; Morell, C. QUBILs-MAS: Free Software for Molecular Descriptors Calculator from Quadratic, Bilinear and Linear Maps Based on Graph-Theoretic Electronic-Density Matrices and Atomic Weightings, version 1.0, CAMD-BIR Unit, CENDA registration number 2373-2012: ToMoCoMD: Villa Clara, 2012.
36. Marrero-Ponce, Y.; Torrens, F.; Alvarado, Y. J.; Rotondo, R. Bond-based global and local (bond, group and bond-type) quadratic indices and their applications to computer-aided molecular design. 1. QSPR studies of diverse sets of organic chemicals. J. Comput.-Aided Mol. Des. 2006, 20, 685−701.
37. Meneses-Marcel, A.; Rivera-Borroto, O. M.; Marrero-Ponce, Y.; Montero, A.; Machado Tugores, Y.; Escario, J. A.; Gomez Barrio, A.; Montero Pereira, D.; Nogal, J. J.; Kouznetsov, V. V.; Ochoa Puentes, C.; Bohorquez, A. R.; Grau, R.; Torrens, F.; Ibarra-Velarde, F.; Aran, V. J. New antitrichomonal drug-like chemicals selected by bond (edge)-based TOMOCOMD-CARDD descriptors. J. Biomol. Screening 2008, 13, 785−794.
38. Casanola-Martin, G. M.; Marrero-Ponce, Y.; Khan, M. T.; Khan, S. B.; Torrens, F.; Perez-Jimenez, F.; Rescigno, A.; Abad, C. Bond-based 2D quadratic fingerprints in QSAR studies: virtual and in vitro tyrosinase inhibitory activity elucidation. Chem. Biol. Drug Des. 2010, 76, 538−545.
39. Castillo-Garit, J. A.; Vega, M. C.; Rolon, M.; Marrero-Ponce, Y.; Kouznetsov, V. V.; Torres, D. F.; Gomez-Barrio, A.; Bello, A. A.; Montero, A.; Torrens, F.; Perez-Gimenez, F. Computational discovery of novel trypanosomicidal drug-like chemicals by using bond-based non-stochastic and stochastic quadratic maps and linear discriminant analysis. Eur. J. Pharm. Sci. 2010, 39, 30−36.
40. Kleandrova, V. V.; Ruso, J. M.; Speck-Planche, A.; Dias Soeiro Cordeiro, M. N. Enabling the Discovery and Virtual Screening of Potent and Safe Antimicrobial Peptides. Simultaneous Prediction of Antibacterial Activity and Cytotoxicity. ACS Comb. Sci. 2016, 18, 490− 498.
41. Hill, T.; Lewicki, P. STATISTICS Methods and Applications: A Comprehensive Reference for Science, Industry and Data Mining; StatSoft: Tulsa, 2006.
42. Statsoft-Team STATISTICA. Data Analysis Software System, version 6.0; StatSoft: Tulsa, 2001.
43. Cronin, M. T. D.; Schultz, T. W. Pitfalls in QSAR. J. Mol. Struct.: THEOCHEM 2003, 622, 39−51.
44. Pearson, K. Notes on regression and inheritance in the case of two parents. Proc. R. Soc. London 1895, 58, 240−242.
45. Chauhan, J. S.; Dhanda, S. K.; Singla, D.; Agarwal, S. M.; Raghava, G. P. QSAR-based models for designing quinazoline/ imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR. PLoS One 2014, 9, e101079.
46. Pearson, K. On lines and planes of closest fit to systems of points in space. Philos. Mag. 1901, 2, 559−572.
47. Hotelling, H. Analysis of a complex of statistical variables into principal components. J. Educ. Psychol. 1933, 24, 417−441.
48. Hotelling, H. Relations between two sets of variates. Biometrika 1936, 28, 321−377.
49. Randic, M. Orthogonal molecular descriptors. New J. Chem. 1991, 15, 517−525.
50. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors; WILEY-VCH Verlag GmbH: Weinheim, 2000.
51. Baskin, I. I.; Skvortsova, M. I.; Stankevich, I. V.; Zefirov, N. S. On the basis of invariants of labeled molecular graphs. J. Chem. Inf. Model. 1995, 35, 527−531.
52. Baskin, I.; Varnek, A. Fragment descriptors in SAR/QSAR/ QSPR studies, molecular similarity analysis and in virtual screening. In Chemoinformatics Approaches to Virtual Screening; Varnek, A., Tropsha, A., Eds; Royal Society of Chemistry: Cambridge, 2008; pp 1−43.
53. Estrada, E.; Uriarte, E.; Montero, A.; Teijeira, M.; Santana, L.; De Clercq, E. A novel approach for the virtual screening and rational design of anticancer compounds. J. Med. Chem. 2000, 43, 1975−1985.
54. Toplak, M.; Mocnik, R.; Polajnar, M.; Bosnic, Z.; Carlsson, L.; Hasselgren, C.; Demsar, J.; Boyer, S.; Zupan, B.; Stalring, J. Assessment of machine learning reliability methods for quantifying the applicability domain of QSAR regression models. J. Chem. Inf. Model. 2014, 54, 431−441.
55. Carrio, P.; Pinto, M.; Ecker, G.; Sanz, F.; Pastor, M. Applicability Domain ANalysis (ADAN): a robust method for assessing the reliability of drug property predictions. J. Chem. Inf. Model. 2014, 54, 1500−1511.
56. Gaspar, H. A.; Marcou, G.; Horvath, D.; Arault, A.; Lozano, S.; Vayer, P.; Varnek, A. Generative topographic mapping-based classification models and their applicability domain: application to the biopharmaceutics Drug Disposition Classification System (BDDCS). J. Chem. Inf. Model. 2013, 53, 3318−3325.
57. Sahigara, F.; Mansouri, K.; Ballabio, D.; Mauri, A.; Consonni, V.; Todeschini, R. Comparison of different approaches to define the applicability domain of QSAR models. Molecules 2012, 17, 4791− 4810.
58. Kaiser, J. Science resources. Chemists want NIH to curtail database. Science 2005, 308, 774.
59. Irwin, J. J.; Shoichet, B. K. ZINC–a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177−182.
60. Gubernator, K.; James, C. A.; Gubernator, N. eMolecules. https://www.emolecules.com/ (accessed February 10, 2017).
61. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3−26.
62. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1999, 1, 55− 68.
63. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615−2623.
64. Todeschini, R.; Consonni, V.; Mauri, A.; Pavan, M. DRAGON for Windows (Software for Molecular Descriptor Calculations), version 5.3; Milano Chemometrics and QSAR Research Group: Milano, 2005.
65. CambridgeSoft. ChemDraw Ultra, version 8.0; CambridgeSoft: Cambridge, MA, 2003.